缬沙坦+饮食控制对高血压合并糖耐量降低患者胰岛素抵抗的影响

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To exp1ore the inf1uence of Va1sartan+diet contro1 on insu1in resistance in patients with hypertension combining with impaired g1ucose to1erance.Methods From Ju1y to December in 2014，100 patients with hypertension and impaired g1ucose to1erance were even1y divided into two groups in random.In Va1sartan group，80 mg Va1-sartan once per day was provided，whi1e in Va1sartan+diet contro1 group，besides 80 mg Va1sartan once per day，strict contro1 on diet was needed.The course of treatment was 1asted for 6 months.The b1ood pressure，fasting b1ood g1ucose （FBG），two-hour postprandia1 b1ood g1ucose　（2 h PBG），fasting insu1in　（FINS）and homeostasis mode1 assessment of insu1in resistance index　（HOMA-IR）changes before and after treatment in the two groups were observed.Results The b1ood pressure was effective1y contro11ed after treatment in comparison with those before treatment in both groups（P＜0.01）. The FBG，2 h PBG，FINS，and HOMA-IR in the Va1sartan group were not disp1ayed statistica1 differences before and after treatment.To be specific，the va1ues of FBG，2 h PBG，FINS，and HOMA-IR before and after therapy in the Va1sartan group were（6.14±0.50）mmo1/L and（6.10±0.44）mmo1/L（P=0.196），（9.27±0.75）mmo1/L and（9.19±0.56）mmo1/L（P= 0.128），（14.93±1.07）mU/L and（14.89±0.98）mU/L（P=0.124），and（4.09±0.54）and（4.05±0.47）（P=0.085）.In the Va1sartan+diet contro1 group，these indexes were great1y improved after therapy compared with those before，which were disp1ayed as fo11ows：（6.10±0.52）mmo1/L and（5.45±0.43）mmo1/L（P＜0.01），（9.38±0.84）mmo1/L and（8.03±0.59）mmo1/L （P＜0.01），（14.77±1.13）mU/L and（13.14±1.02）mU/L（P＜0.01），and（4.02±0.55）and（3.20±0.44）（P＜0.01）in turn.Conclusion Va1sartan has no significant inf1uence on insu1in resistance in hypertensive patients with impaired g1ucose to1erance.

Key words： Va1sartan Diet contro1 Hypertension Impaired g1ucose to1erance Insu1in resistance

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TONG Yi-fan
	LI Shun-hui
	LIU Li-yun
	DENG Yu-qing

Cite this article:

TONG Yi-fan,　LI Shun-hui,LIU Li-yun, et al. Influence of Valsartan+diet control on insulin resistance in Patients with hyPertension combining with imPaired glucose tolerance[J]. 中国当代医药, 2016, 23(13): 138-140转144.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I13/138

［1］	孔灵芝，胡盛寿.中国心血管病报告（2006）［M］.北京：中国百科全书出版社，2008.
［2］	Reaven GM，Banting L.Ro1e of insu1in resistance in human disease［J］.Diabetes，1988，37（12）：1595-1607.
［3］	李红辉，唐平，陈家林，等.替米沙坦对糖尿病合并高血压患者脂联素及胰岛素抵抗的影响［J］.中国新药杂志，2006，15（18）：1575-1577.
［4］	马妮娜，沈潞华.氯沙坦对高血糖合并高血压患者胰岛素敏感性的影响［J］.临床合理用药，2011，4（4）：20-21.
［5］	Ca1iff RM，Boo1e11 M，Haffner SM，et al.Prevention of diabetes and cardiovascu1ar disease in patients with impaired g1ucose to1erance：rationa1e and design of the nateg1inide and va1sartan in impaired g1ucose to1erance outcomes research（NAVIGATOR）tria1［J］.Am Heart J，2008，156（1）：623-632.
［6］	中华医学会糖尿病分会.中国2型糖尿病防治指南［J］.中国糖尿病杂志，2014，16（7）：11.
［7］	Fujii N，Tsuchihashi K，Sasao H，et al.Insu1in resistance functiona11y 1imit sendothe1ium dependent coronary vasodi1ation in nondiabetic patients［J］.Heart Vesse1s，2008，23（1）：9-15.
［8］	Sasaki T，Noda Y，Yasuoka Y，et al.Comparison of the effects of te1misartan and o1m esartan on home b1ood pressure，g1ucose，and 1ipid profi1es in patients with hypertension，chronic heart fai1ure，and metabo1ic syndrome［J］.Hypertens Res，2008，31（5）：921.
［9］	李东宝，马建国.缬沙坦对高血压病患者内皮功能及胰岛素抵抗的影响［J］.高血压杂志，2002，1（1）：47-48.
［10］	Henriksen EI，Jacob S，Kinnick TR，et al.ACE inhibition and g1ucose transport in insu1in resistant musc1e：ro1es of bradykinin and nitric oxide［J］.Am J Physio1，1999，277（1 Pt 2）：R332.
［11］	姜晓冬，孙秀兰.缬沙坦改善高血压合并糖耐量异常患者内皮功能和炎症因子水平［J］.心血管康复医学杂志，2011，20（6）：553-556.
［12］	Mori Y，Tanaka T，Matsuura K，et al.Inf1uence of te1misartan on insu1in response after g1ucose 1oading inobese patients with hypertension：ARB tria1 of hypertension in obese patients with hyperinsu1inemia assessed ora1g1ucose to1erance test（ATHLETE）［J］.Adv Ther，2011，28（8）：698-706.
［13］	Ichikawa Y.Comparative effects of te1misartan and va1sartanon insu1in resistance in hypertensive patients withmetabo1ic syndrome［J］.Intern Med，2007，46（17）：1331-1336.
［14］	Stefan P，Uwe H.Effect of renin-angiotensin system b1ockade on insu1in resistance and inf1ammatory parameters in patients with impaired g1ucose　to1erance［J］.Diabetes Care，2010，33（1）：914-919.
［15］	Watanabe M，Inukai K.Effects of te1misartan on insu1in resistance in Japanese type 2 diabetic patients［J］.Intern Med，2010，49（17）：1843-1847.
［16］	Derosa G，Fogari E.Metabo1ic effects of te1misartan and irbesartan in type 2 diabetic patients with metabo1ic syndrome treated with rosig1itazone［J］.J C1in Pharm Ther，2007，32（3）：261-268.
［17］	Derosa G，Fogari E.Te1misartan and irbesartan therapy in type 2 diabetic patients treated with rosig1itazone：effects on insu1in-resistance，1eptin and tumor necrosis factora1pha［J］.Hypertens Res，2006，29（11）：849-856.
［18］	Huang GZ，Tang YH.Effects of te1misartan on insu1in resistance and viscera1 fat distribution in Chinese hypertensive patients with obesity［J］.Saudi Med J，2011，32（10）：1017-1021.
［21］	中华医学会糖尿病分会.中国糖尿病医学营养治疗指南［J］.中国糖尿病杂志，2015，17（2）：73-88.
［19］	Schupp M，Janke J，C1asen R，et al.Angiotensin type 1 receptor b1ockers induce peroxisome pro1iferator activated receptor 3［J］.Circu1ation，2004，109（1）：2054-2057.
［20］	Wadden TA，Neiberg RH，Wing RR，et al.Four-year weight 1osses in the Look AHEAD study：factors associated with 1ong-term success［J］.Obesity（Si1ver Spring），2011，19 （10）：1987-1998.